CVS Health Q3 2025 Earnings Report and Full-Year Guidance Update

CVS Health Corporation reported its third quarter 2025 financial results, highlighting a record high total revenue of $102.9 billion, a 7.8% increase compared to the prior year. However, the company reported a GAAP diluted loss per share of $3.13, primarily due to a $5.7 billion goodwill impairment charge related to the Health Care Delivery reporting unit. Adjusted EPS for the quarter was $1.60, up from $1.09 in the prior year. The company also updated its full-year 2025 guidance, raising the Adjusted EPS range to $6.55 to $6.65 from $6.30 to $6.40, while updating the GAAP diluted earnings (loss) per share guidance range to $(0.34) to $(0.24) from $3.84 to $3.94. Operational highlights include Aetna receiving industry-leading Medicare Advantage Star Ratings results and the launch of the annual vaccination campaign at CVS Pharmacy and MinuteClinic locations nationwide. The company's CEO, David Joyner, emphasized the focus on operational and financial improvement across its businesses.